Precision medicines biotech Frontier Medicines is leaving behind an unknown number of staffers as it refocuses resources to ...

Research co-led by University of Toronto researchers and Insilico Medicine has demonstrated the potential of quantum ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

CAYMAN ISLANDS - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm focusing on RNA interference (RNAi) treatments, ...

Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will ...

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on ...

Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified ...

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...